<ul>
<li>Corbus Pharmaceuticals 股票：年初至今激增 342%</li>
</ul>
<p>Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - 免费报告) - Lifesci Capital 的股票研究人员在 2026 年第二季度的研究报告中发布了对 Corbus Pharmaceuticals 的每股收益（EPS）预测，该报告于 5 月 13 日星期三发给客户和投资者。Lifesci Capital 分析师 O. Mccammon 预测该生物制药公司本季度每股收益为（$1.24）。对 Corbus Pharmaceuticals 当前全年的共识预期为每股（$4.78）。Lifesci Capital 还发布了对 Corbus Pharmaceuticals 2026 年第四季度每股收益的预测为（$1.51）和 2026 财年的每股收益为（$5.07）。</p>
<p>获取 <strong>Corbus Pharmaceuticals</strong> 的提醒：</p>
<p>其他几位分析师也对 CRBP 发布了报告。华尔街禅在 4 月 25 日星期六的报告中将 Corbus Pharmaceuticals 的评级从 “强烈卖出” 上调至 “卖出”。Weiss Ratings 在 4 月 20 日星期一的报告中重申了对 Corbus Pharmaceuticals 股票的 “卖出（d-）” 评级。Oppenheimer 在周三的报告中将 Corbus Pharmaceuticals 的目标价从 57.00 美元下调至 54.00 美元，并对该公司设定了 “跑赢大盘” 的评级。Jefferies Financial Group 在周二的报告中将 Corbus Pharmaceuticals 的目标价从 36.00 美元下调至 33.00 美元，并对该公司设定了 “买入” 评级。最后，Guggenheim 在周三的报告中重申了 “买入” 评级，并对 Corbus Pharmaceuticals 股票设定了 45.00 美元的目标价。一位股票研究分析师对该股票给予了强烈买入评级，八位分析师给予了买入评级，两位分析师给予了卖出评级。根据 MarketBeat 的数据，Corbus Pharmaceuticals 目前的共识评级为 “适度买入”，平均目标价为 42.33 美元。</p>
<ul>
<li>Corbus Pharmaceuticals NASDAQ: CRBP 发出强烈买入信号</li>
</ul>
<p><strong>查看我们最新的 CRBP 股票报告</strong></p>
<h2>Corbus Pharmaceuticals 股价上涨 6.3%</h2>
<p>NASDAQ:CRBP 的股票在周四开盘价为 12.15 美元。Corbus Pharmaceuticals 的一年低点为 6.72 美元，一年高点为 20.56 美元。该公司的 50 日简单移动平均线为 9.77 美元，200 日简单移动平均线为 9.66 美元。该公司的市值为 2.1554 亿美元，市盈率为-2.09，贝塔值为 2.68。</p>
<p>Corbus Pharmaceuticals (NASDAQ:CRBP - 获取免费报告) 最近在 5 月 12 日星期二公布了季度财报。该生物制药公司报告的每股收益为（$1.23），超出共识预期的（$1.26）0.03 美元。</p>
<h2>对 Corbus Pharmaceuticals 的对冲基金看法</h2>
<p>机构投资者最近对该公司的持仓进行了调整。Assenagon Asset Management S.A. 在第四季度将其在 Corbus Pharmaceuticals 股票中的持股比例增加了 120.2%。Assenagon Asset Management S.A. 现在拥有 187,956 股该生物制药公司的股票，价值 1,530,000 美元，在此期间又购买了 102,609 股。Aberdeen Group plc 在第四季度将其在 Corbus Pharmaceuticals 股票中的持股比例增加了 602.2%。Aberdeen Group plc 现在拥有 1,321,750 股该生物制药公司的股票，价值 10,759,000 美元，在此期间又购买了 1,133,519 股。HighVista Strategies LLC 在第三季度将其在 Corbus Pharmaceuticals 股票中的持股比例增加了 56.8%。HighVista Strategies LLC 现在拥有 118,027 股该生物制药公司的股票，价值 1,493,000 美元，在此期间又购买了 42,735 股。Virtu Financial LLC 在第四季度收购了 Corbus Pharmaceuticals 的新股份，价值约 88,000 美元。最后，Engineers Gate Manager LP 在第四季度收购了 Corbus Pharmaceuticals 的新股份，价值约 140,000 美元。64.64% 的股票目前由机构投资者持有。</p>
<h2>Corbus Pharmaceuticals 主要新闻</h2>
<p>以下是本周影响 Corbus Pharmaceuticals 的主要新闻：</p>
<ul>
<li>积极情绪：Corbus 报告 2026 年第一季度每股收益为 <strong>($1.23)</strong>，超出共识预期 0.03 美元，表明本季度的结果略好于预期。</li>
<li>积极情绪：该公司表示已就 <strong>CRB-701</strong> 在头颈部鳞状细胞癌和宫颈癌的注册路径达成广泛的 FDA 一致意见，这是朝着今年夏天进行注册研究的重要监管步骤。</li>
<li>积极情绪：Corbus 完成了 <strong>CANYON-1</strong> 肥胖研究的入组，预计将在夏季发布 16 周的顶线数据，增加了近期催化剂。</li>
<li>积极情绪：HC Wainwright 和 LifeSci Capital <strong>提高了 2026-2030 年的多项收益预期</strong>，反映出对公司长期收益轨迹的改善预期。</li>
<li>积极情绪：几家券商维持了建设性的观点，包括 <strong>Guggenheim 的买入评级</strong> 和 <strong>Oppenheimer 的跑赢大盘评级</strong>，显示出分析师的持续信心。Corbus Pharmaceuticals 将参加即将举行的投资者会议。</li>
<li>中性情绪：Corbus 将在纽约的即将举行的投资者会议上进行演讲，这可能会增加可见度，但本身并不会改变基本面。Corbus Pharmaceuticals 将参加即将举行的投资者会议。</li>
<li>消极情绪：第一季度净亏损扩大至约 <strong>2300 万美元</strong>，运营费用增加，突显出 Corbus 仍然是一家高烧钱的临床阶段生物技术公司，尚未盈利。</li>
<li>消极情绪：Oppenheimer <strong>将其目标价</strong> 从 57 美元下调至 54 美元，尽管仍然看涨，但可能抑制了一些热情。</li>
</ul>
<h2>关于 Corbus Pharmaceuticals</h2>
<p>(获取免费报告)</p>
<p>Corbus Pharmaceuticals Holdings, Inc 是一家临床阶段的生物制药公司，致力于开发和商业化针对罕见、危及生命的炎症和纤维化疾病的治疗候选药物。该公司的主要研究治疗药物 lenabasum 是一种合成的口服大麻素受体 2 型（CB2）激动剂，旨在通过利用身体的固有解决途径来消除慢性炎症。Corbus 通过推进小分子化合物的临床前和临床研究，来满足自身免疫和炎症疾病中的未满足医疗需求。</p>
<p>lenabasum 目前正在进行针对弥漫性皮肤系统性硬化症（dcSSc）的三期临床试验，以及针对囊性纤维化相关炎症的二期研究。</p>
<h2>另见</h2>
<ul>
<li>我们更看好的五只股票，胜过 Corbus Pharmaceuticals</li>
<li>Oklo 股票可能准备迎来另一次大幅上涨</li>
<li>D-Wave 的财报看起来疲软，但投资者可能错过了这一点</li>
<li>随着 AI 反馈循环的加剧，Nebius 的上行空间扩大</li>
<li>内部交易：Okta 和 Abbott 看到买入，Micron 内部人士卖出</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1JCUA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="650" height="325" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1JCUA"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资$1,000 在 Corbus Pharmaceuticals 吗？</h2>
<p>在考虑投资 Corbus Pharmaceuticals 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前立即购买……而 Corbus Pharmaceuticals 并不在名单上。</p>
<p>虽然 Corbus Pharmaceuticals 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

Corbus制药控股

动态生物技术与基因组 ETF - Invesco

2 倍做多纳斯达克生物技术 ETF - ProShares

生物科技 ETF - VanEck Vectors

医药突破 ETF - ALPS

纽交所高增长板生物技术指数 ETF - First Trust

标普生物技术 ETF - SPDR

标普生物技术 3 倍做多 - Direxion

纳斯达克生物科技指数 ETF - iShares Nasdaq

IBBQ

<p>Corbus 制药控股公司（NASDAQ:CRBP）预计将在 2026 年第二季度报告每股收益（EPS）为（$1.24），根据 Lifesci Capital 的预测。该公司今年迄今股价上涨了 342%，全年每股收益的当前共识估计为（$4.78）。分析师的评级各不相同，其中有一项强烈买入、八项买入和两项卖出评级。Corbus 最近报告的第一季度每股收益为（$1.23），超出预期，并且在 CRB-701 的注册路径上达成了 FDA 的对齐。该股票开盘价为$12.15，市值为 2.1554 亿美元，评级共识为 “适度买入”</p>

<ul>
<li>Corbus Pharmaceuticals stock: An explosive 342% YTD surge</li>
</ul>
<div class="lb-trans"><ul>
<li>Corbus Pharmaceuticals 股票：年初至今激增 342%</li>
</ul>
</div><p>Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Free Report) - Equities researchers at Lifesci Capital issued their Q2 2026 earnings per share (EPS) estimates for Corbus Pharmaceuticals in a research report issued to clients and investors on Wednesday, May 13th. Lifesci Capital analyst O. Mccammon forecasts that the biopharmaceutical company will post earnings per share of ($1.24) for the quarter. The consensus estimate for Corbus Pharmaceuticals' current full-year earnings is ($4.78) per share. Lifesci Capital also issued estimates for Corbus Pharmaceuticals' Q4 2026 earnings at ($1.51) EPS and FY2026 earnings at ($5.07) EPS.</p>
<div class="lb-trans"><p>Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - 免费报告) - Lifesci Capital 的股票研究人员在 2026 年第二季度的研究报告中发布了对 Corbus Pharmaceuticals 的每股收益（EPS）预测，该报告于 5 月 13 日星期三发给客户和投资者。Lifesci Capital 分析师 O. Mccammon 预测该生物制药公司本季度每股收益为（$1.24）。对 Corbus Pharmaceuticals 当前全年的共识预期为每股（$4.78）。Lifesci Capital 还发布了对 Corbus Pharmaceuticals 2026 年第四季度每股收益的预测为（$1.51）和 2026 财年的每股收益为（$5.07）。</p>
</div><p>Get <strong>Corbus Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Corbus Pharmaceuticals</strong> 的提醒：</p>
</div><p>Several other analysts have also issued reports on CRBP. Wall Street Zen upgraded Corbus Pharmaceuticals from a &#34;strong sell&#34; rating to a &#34;sell&#34; rating in a report on Saturday, April 25th. Weiss Ratings reiterated a &#34;sell (d-)&#34; rating on shares of Corbus Pharmaceuticals in a report on Monday, April 20th. Oppenheimer cut their price objective on Corbus Pharmaceuticals from $57.00 to $54.00 and set an &#34;outperform&#34; rating for the company in a report on Wednesday. Jefferies Financial Group cut their price objective on Corbus Pharmaceuticals from $36.00 to $33.00 and set a &#34;buy&#34; rating for the company in a report on Tuesday. Finally, Guggenheim reiterated a &#34;buy&#34; rating and set a $45.00 price objective on shares of Corbus Pharmaceuticals in a report on Wednesday. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and two have issued a Sell rating to the company's stock. Based on data from MarketBeat, Corbus Pharmaceuticals currently has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $42.33.</p>
<div class="lb-trans"><p>其他几位分析师也对 CRBP 发布了报告。华尔街禅在 4 月 25 日星期六的报告中将 Corbus Pharmaceuticals 的评级从 “强烈卖出” 上调至 “卖出”。Weiss Ratings 在 4 月 20 日星期一的报告中重申了对 Corbus Pharmaceuticals 股票的 “卖出（d-）” 评级。Oppenheimer 在周三的报告中将 Corbus Pharmaceuticals 的目标价从 57.00 美元下调至 54.00 美元，并对该公司设定了 “跑赢大盘” 的评级。Jefferies Financial Group 在周二的报告中将 Corbus Pharmaceuticals 的目标价从 36.00 美元下调至 33.00 美元，并对该公司设定了 “买入” 评级。最后，Guggenheim 在周三的报告中重申了 “买入” 评级，并对 Corbus Pharmaceuticals 股票设定了 45.00 美元的目标价。一位股票研究分析师对该股票给予了强烈买入评级，八位分析师给予了买入评级，两位分析师给予了卖出评级。根据 MarketBeat 的数据，Corbus Pharmaceuticals 目前的共识评级为 “适度买入”，平均目标价为 42.33 美元。</p>
</div><ul>
<li>Corbus Pharmaceuticals NASDAQ: CRBP Gives a Bold Buy Signal</li>
</ul>
<div class="lb-trans"><ul>
<li>Corbus Pharmaceuticals NASDAQ: CRBP 发出强烈买入信号</li>
</ul>
</div><p><strong>Check Out Our Latest Stock Report on CRBP</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的 CRBP 股票报告</strong></p>
</div><h2>Corbus Pharmaceuticals Trading Up 6.3%</h2>
<div class="lb-trans"><h2>Corbus Pharmaceuticals 股价上涨 6.3%</h2>
</div><p>Shares of NASDAQ:CRBP opened at $12.15 on Thursday. Corbus Pharmaceuticals has a 1 year low of $6.72 and a 1 year high of $20.56. The business has a fifty day simple moving average of $9.77 and a 200 day simple moving average of $9.66. The firm has a market cap of $215.54 million, a price-to-earnings ratio of -2.09 and a beta of 2.68.</p>
<div class="lb-trans"><p>NASDAQ:CRBP 的股票在周四开盘价为 12.15 美元。Corbus Pharmaceuticals 的一年低点为 6.72 美元，一年高点为 20.56 美元。该公司的 50 日简单移动平均线为 9.77 美元，200 日简单移动平均线为 9.66 美元。该公司的市值为 2.1554 亿美元，市盈率为-2.09，贝塔值为 2.68。</p>
</div><p>Corbus Pharmaceuticals (NASDAQ:CRBP - Get Free Report) last announced its quarterly earnings data on Tuesday, May 12th. The biopharmaceutical company reported ($1.23) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.26) by $0.03.</p>
<div class="lb-trans"><p>Corbus Pharmaceuticals (NASDAQ:CRBP - 获取免费报告) 最近在 5 月 12 日星期二公布了季度财报。该生物制药公司报告的每股收益为（$1.23），超出共识预期的（$1.26）0.03 美元。</p>
</div><h2>Hedge Funds Weigh In On Corbus Pharmaceuticals</h2>
<div class="lb-trans"><h2>对 Corbus Pharmaceuticals 的对冲基金看法</h2>
</div><p>Institutional investors have recently made changes to their positions in the business. Assenagon Asset Management S.A. increased its stake in shares of Corbus Pharmaceuticals by 120.2% in the fourth quarter. Assenagon Asset Management S.A. now owns 187,956 shares of the biopharmaceutical company's stock worth $1,530,000 after purchasing an additional 102,609 shares during the period. Aberdeen Group plc increased its stake in shares of Corbus Pharmaceuticals by 602.2% in the fourth quarter. Aberdeen Group plc now owns 1,321,750 shares of the biopharmaceutical company's stock worth $10,759,000 after purchasing an additional 1,133,519 shares during the period. HighVista Strategies LLC increased its stake in shares of Corbus Pharmaceuticals by 56.8% in the third quarter. HighVista Strategies LLC now owns 118,027 shares of the biopharmaceutical company's stock worth $1,493,000 after purchasing an additional 42,735 shares during the period. Virtu Financial LLC acquired a new stake in Corbus Pharmaceuticals during the fourth quarter worth about $88,000. Finally, Engineers Gate Manager LP acquired a new stake in Corbus Pharmaceuticals during the fourth quarter worth about $140,000. 64.64% of the stock is currently owned by institutional investors.</p>
<div class="lb-trans"><p>机构投资者最近对该公司的持仓进行了调整。Assenagon Asset Management S.A. 在第四季度将其在 Corbus Pharmaceuticals 股票中的持股比例增加了 120.2%。Assenagon Asset Management S.A. 现在拥有 187,956 股该生物制药公司的股票，价值 1,530,000 美元，在此期间又购买了 102,609 股。Aberdeen Group plc 在第四季度将其在 Corbus Pharmaceuticals 股票中的持股比例增加了 602.2%。Aberdeen Group plc 现在拥有 1,321,750 股该生物制药公司的股票，价值 10,759,000 美元，在此期间又购买了 1,133,519 股。HighVista Strategies LLC 在第三季度将其在 Corbus Pharmaceuticals 股票中的持股比例增加了 56.8%。HighVista Strategies LLC 现在拥有 118,027 股该生物制药公司的股票，价值 1,493,000 美元，在此期间又购买了 42,735 股。Virtu Financial LLC 在第四季度收购了 Corbus Pharmaceuticals 的新股份，价值约 88,000 美元。最后，Engineers Gate Manager LP 在第四季度收购了 Corbus Pharmaceuticals 的新股份，价值约 140,000 美元。64.64% 的股票目前由机构投资者持有。</p>
</div><h2>Key Corbus Pharmaceuticals News</h2>
<div class="lb-trans"><h2>Corbus Pharmaceuticals 主要新闻</h2>
</div><p>Here are the key news stories impacting Corbus Pharmaceuticals this week:</p>
<div class="lb-trans"><p>以下是本周影响 Corbus Pharmaceuticals 的主要新闻：</p>
</div><ul>
<li>Positive Sentiment: Corbus reported Q1 2026 EPS of <strong>($1.23)</strong>, beating consensus by $0.03, which suggests results were slightly better than expected for the quarter.</li>
<li>Positive Sentiment: The company said it reached broad FDA alignment on the registration path for <strong>CRB-701</strong> in head and neck squamous cell carcinoma and cervical cancer, a meaningful regulatory step toward a registrational study this summer.</li>
<li>Positive Sentiment: Corbus completed enrollment in the <strong>CANYON-1</strong> obesity study for <strong>CRB-913</strong>, with topline 16-week data expected this summer, adding a near-term catalyst.</li>
<li>Positive Sentiment: HC Wainwright and LifeSci Capital <strong>raised multiple earnings estimates</strong> across 2026-2030, reflecting improved expectations for the company’s long-term earnings trajectory.</li>
<li>Positive Sentiment: Several brokerages maintained constructive views, including <strong>Guggenheim’s buy rating</strong> and <strong>Oppenheimer’s outperform rating</strong>, signaling continued analyst confidence. Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences</li>
<li>Neutral Sentiment: Corbus will present at upcoming investor conferences in New York, which may increase visibility but does not by itself change fundamentals. Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences</li>
<li>Negative Sentiment: Q1 net loss widened to about <strong>$23.0 million</strong> and operating expenses increased, underscoring that Corbus remains a high-burn clinical-stage biotech with no profits yet.</li>
<li>Negative Sentiment: Oppenheimer <strong>cut its price target</strong> from $57 to $54, which is still bullish but may have tempered some enthusiasm.</li>
</ul>
<div class="lb-trans"><ul>
<li>积极情绪：Corbus 报告 2026 年第一季度每股收益为 <strong>($1.23)</strong>，超出共识预期 0.03 美元，表明本季度的结果略好于预期。</li>
<li>积极情绪：该公司表示已就 <strong>CRB-701</strong> 在头颈部鳞状细胞癌和宫颈癌的注册路径达成广泛的 FDA 一致意见，这是朝着今年夏天进行注册研究的重要监管步骤。</li>
<li>积极情绪：Corbus 完成了 <strong>CANYON-1</strong> 肥胖研究的入组，预计将在夏季发布 16 周的顶线数据，增加了近期催化剂。</li>
<li>积极情绪：HC Wainwright 和 LifeSci Capital <strong>提高了 2026-2030 年的多项收益预期</strong>，反映出对公司长期收益轨迹的改善预期。</li>
<li>积极情绪：几家券商维持了建设性的观点，包括 <strong>Guggenheim 的买入评级</strong> 和 <strong>Oppenheimer 的跑赢大盘评级</strong>，显示出分析师的持续信心。Corbus Pharmaceuticals 将参加即将举行的投资者会议。</li>
<li>中性情绪：Corbus 将在纽约的即将举行的投资者会议上进行演讲，这可能会增加可见度，但本身并不会改变基本面。Corbus Pharmaceuticals 将参加即将举行的投资者会议。</li>
<li>消极情绪：第一季度净亏损扩大至约 <strong>2300 万美元</strong>，运营费用增加，突显出 Corbus 仍然是一家高烧钱的临床阶段生物技术公司，尚未盈利。</li>
<li>消极情绪：Oppenheimer <strong>将其目标价</strong> 从 57 美元下调至 54 美元，尽管仍然看涨，但可能抑制了一些热情。</li>
</ul>
</div><h2>About Corbus Pharmaceuticals</h2>
<div class="lb-trans"><h2>关于 Corbus Pharmaceuticals</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(获取免费报告)</p>
</div><p>Corbus Pharmaceuticals Holdings, Inc is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of therapeutic candidates for rare, life-threatening inflammatory and fibrotic diseases. The company's lead investigational therapy, lenabasum, is a synthetic, oral cannabinoid receptor type 2 (CB2) agonist designed to resolve chronic inflammation by harnessing the body's innate resolution pathways. Corbus operates by advancing small-molecule compounds through preclinical and clinical studies to address unmet medical needs in autoimmune and inflammatory disorders.</p>
<div class="lb-trans"><p>Corbus Pharmaceuticals Holdings, Inc 是一家临床阶段的生物制药公司，致力于开发和商业化针对罕见、危及生命的炎症和纤维化疾病的治疗候选药物。该公司的主要研究治疗药物 lenabasum 是一种合成的口服大麻素受体 2 型（CB2）激动剂，旨在通过利用身体的固有解决途径来消除慢性炎症。Corbus 通过推进小分子化合物的临床前和临床研究，来满足自身免疫和炎症疾病中的未满足医疗需求。</p>
</div><p>Lenabasum is currently under evaluation in a Phase 3 clinical trial for diffuse cutaneous systemic sclerosis (dcSSc) and in a Phase 2 study for cystic fibrosis–related inflammation.</p>
<div class="lb-trans"><p>lenabasum 目前正在进行针对弥漫性皮肤系统性硬化症（dcSSc）的三期临床试验，以及针对囊性纤维化相关炎症的二期研究。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than Corbus Pharmaceuticals</li>
<li>Oklo Stock Could Be Ready for Another Massive Run</li>
<li>D-Wave Earnings Looked Weak, But Investors May Be Missing This</li>
<li>Nebius Upside Expands as AI Feedback Loop Intensifies</li>
<li>Insider Trades: Okta and Abbott See Buys, Micron Insiders Sell</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过 Corbus Pharmaceuticals</li>
<li>Oklo 股票可能准备迎来另一次大幅上涨</li>
<li>D-Wave 的财报看起来疲软，但投资者可能错过了这一点</li>
<li>随着 AI 反馈循环的加剧，Nebius 的上行空间扩大</li>
<li>内部交易：Okta 和 Abbott 看到买入，Micron 内部人士卖出</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1JCUA" alt="" original-src="https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx?Prefix=NASDAQ&amp;Symbol=CRBP"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Corbus Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资$1,000 在 Corbus Pharmaceuticals 吗？</h2>
</div><p>Before you consider Corbus Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑投资 Corbus Pharmaceuticals 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Corbus Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前立即购买……而 Corbus Pharmaceuticals 并不在名单上。</p>
</div><p>While Corbus Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Corbus Pharmaceuticals 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

经纪商对 Corbus Pharma 第二季度收益的预测